Long-Term Cardiovascular Risk for Endometrial Cancer Survivors
TUESDAY, May 8, 2018 -- Endometrial cancer survivors have an elevated risk of various adverse long-term cardiovascular outcomes, according to a study published online May 8 in the Journal of the National Cancer Institute.
Sean Soisson, from the University of Utah School of Medicine in Salt Lake City, and colleagues identified cohorts of 2,648 endometrial cancer survivors diagnosed between 1997 and 2012 and 10,503 age-matched women from the general population. Electronic medical records and statewide ambulatory surgery and inpatient data were used to identify cardiovascular disease diagnoses. Hazard ratios were estimated at one to five, more than five to 10, and more than 10 years after cancer diagnosis.
The researchers found that there were increased cardiovascular risks among endometrial cancer survivors for phlebitis, thrombophlebitis, and thromboembolism (hazard ratio, 2.07); pulmonary heart disease (hazard ratio, 1.74); and atrial fibrillation (hazard ratio, 1.5) between one and five years after diagnosis. Some elevated risk persisted for cardiovascular diseases at more than five to 10 years. Patients who also had radiation therapy and/or chemotherapy had an elevated risk for heart and circulatory system disorders between one and five years after cancer diagnosis compared with patients who had surgery. Among endometrial cancer survivors, older age and obesity were also risk factors for hypertension and heart disease.
"This study suggests that increased monitoring for cardiovascular diseases may be necessary for endometrial cancer patients for 10 years after cancer diagnosis," the authors write.
© 2020 HealthDay. All rights reserved.
Posted: May 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.